Small Animal

Targeted pain relief from the earliest diagnosed stages of canine Osteoarthritis (OA) Galliprant is a first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID. It specifically targets the EP4 receptor, the primary mediator of canine OA pain and inflammation1. You can start treatment from the earliest diagnosed stages.

Librela is the first-of-its-kind veterinary medicine that contains bedinvetmab, a monoclonal antibody that binds to Nerve Growth Factor (NGF), a key player in OA pain and in doing so reduces pain. It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in its metabolism and elimination from the body; bedinvetmab also produces minimal gastrointestinal (GI) impact.After one injection of Librela, dogs with osteoarthritis exhibited increased mobility and decreased pain.

Librela is the first-of-its-kind veterinary medicine that contains bedinvetmab, a monoclonal antibody that binds to Nerve Growth Factor (NGF), a key player in OA pain and in doing so reduces pain. It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in its metabolism and elimination from the body; bedinvetmab also produces minimal gastrointestinal (GI) impact.After one injection of Librela, dogs with osteoarthritis exhibited increased mobility and decreased pain.

Librela is the first-of-its-kind veterinary medicine that contains bedinvetmab, a monoclonal antibody that binds to Nerve Growth Factor (NGF), a key player in OA pain and in doing so reduces pain. It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in its metabolism and elimination from the body; bedinvetmab also produces minimal gastrointestinal (GI) impact.After one injection of Librela, dogs with osteoarthritis exhibited increased mobility and decreased pain.

Librela is the first-of-its-kind veterinary medicine that contains bedinvetmab, a monoclonal antibody that binds to Nerve Growth Factor (NGF), a key player in OA pain and in doing so reduces pain. It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in its metabolism and elimination from the body; bedinvetmab also produces minimal gastrointestinal (GI) impact.After one injection of Librela, dogs with osteoarthritis exhibited increased mobility and decreased pain.

Librela is the first-of-its-kind veterinary medicine that contains bedinvetmab, a monoclonal antibody that binds to Nerve Growth Factor (NGF), a key player in OA pain and in doing so reduces pain. It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in its metabolism and elimination from the body; bedinvetmab also produces minimal gastrointestinal (GI) impact.After one injection of Librela, dogs with osteoarthritis exhibited increased mobility and decreased pain.

Dogs: Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery. Active ingredient: Meloxicam

Dogs: Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery. Active ingredient: Meloxicam

Alleviates inflammation and pain in chronic musculo-skeletal disorders in cats. Active ingredient: Meloxicam

Alleviates inflammation and pain in chronic musculo-skeletal disorders in cats. Active ingredient: Meloxicam

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs Active ingredient: Meloxicam

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs Active ingredient: Meloxicam